Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes

Nephrology

Volumn 21, Issue 5, 2016, Pages 423-431

  Gangadharan Komala, Muralikrishna ^a   Gross, Simon ^a   Zaky, Amgad ^a   Pollock, Carol ^a   Panchapakesan, Usha ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

diabetic nephropathy; DPP4 inhibitors; saxagliptin; tubulointerstitial fibrosis

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRONECTIN; GLUCOSE; INSULIN GLARGINE; SAXAGLIPTIN; STREPTOZOCIN; TELMISARTAN; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, MOUSE; GLUCOSE BLOOD LEVEL; INSULIN; NOS3 PROTEIN, MOUSE; RELA PROTEIN, MOUSE; SMAD2 PROTEIN; SMAD2 PROTEIN, MOUSE; SMAD3 PROTEIN; SMAD3 PROTEIN, MOUSE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTIFIBROTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG ACTIVITY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY PARENCHYMA; MACROPHAGE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; RENAL PROTECTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMICALLY INDUCED; DEFICIENCY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; GENETICS; GLOMERULONEPHRITIS; HYPERTROPHY; KIDNEY; KNOCKOUT MOUSE; METABOLISM; NEPHRITIS, INTERSTITIAL; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADAMANTANE; ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIPEPTIDES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FIBRONECTINS; FIBROSIS; GLOMERULONEPHRITIS; HYPERTROPHY; INSULIN; KIDNEY; MALE; MICE, KNOCKOUT; NEPHRITIS, INTERSTITIAL; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; STREPTOZOCIN; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA;

EID: 84964226640     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12618     Document Type: Article

References (13)

1. Ansorge S, Nordhoff K, Bank U, et al., Novel aspects of cellular action of dipeptidyl peptidase IV/CD26. Biol. Chem. 2011; 392: 153-68.
2. Mentlein R,. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 1999; 85: 9-24.
3. Lone AM, Nolte WM, Tinoco AD, Saghatelian A,. Peptidomics of the prolyl peptidases. AAPS J. 2010; 12: 483-91.
4. Panchapakesan U, Gross S, Gangadharan Komala M, Pegg K, Pollock C,. DPP4 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? J Diabetes Metab 2013; S9: 007.
5. Liu WJ, Xie SH, Liu YN, et al., Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 2012; 340: 248-55.
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
7. Mega C, de Lemos ET, Vala H, et al., Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp. Diabetes Res. 2011; 2011: 162092.
8. Gangadharan Komala M, Gross S, Mudaliar H, et al., Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One 2014; 9: e108994.
9. Panchapakesan U, Pollock CA,. DPP-4 inhibitors-renoprotection in diabetic nephropathy? Diabetes 2014; 63: 1829-30.
10. Marchetti C, Di Carlo A, Facchiano F, et al., High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia 2012; 55: 236-44.
11. Nin JW, Ferreira I, Schalkwijk CG, et al., Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB prospective complications study. Eur J Endocrinol 2012; 166: 325-32.
12. Mason RP, Jacob RF, Kubant R, Ciszewski A, Corbalan JJ, Malinski T,. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J. Cardiovasc. Pharmacol. 2012; 60: 467-73.
13. Kodera R, Shikata K, Takatsuka T, et al., Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem. Biophys. Res. Commun. 2014; 443: 828-33.